galectin-3

galectin-3

A 30-kD protein, a beta-galactosidase-binding lectin encoded by LGALS3 on chromosome 14q22.3, which is thought to be involved in cell growth, adhesion, acute inflammation (neutrophil activation and adhesion, chemoattraction of macrophages, and activation of mast cells), mRNA splicing and processing, and apoptosis.

Normal expression
Mainly in the nucleus of epithelial and immune cells, neutrophils, and vascular endothelium.

Abnormal expression
Over-expression is linked to malignant transformation and metastases in carcinomas of the breast, colon, tongue, liver, and thyroid.
Mentioned in ?
References in periodicals archive ?
Galectin's lead drug,GR-MD-02 is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases.
Galectin Therapeutics spikes higher after updating study results
In fact, a study from the Karmanos Cancer Institute at Wayne State University linked galectin-3 to a number of negative cancer characteristics, including aggressiveness, growth, dissemination of cancer cells through the bloodstream, and tumor growth.
This Canning Ingredient Might Help You Survive Cancer
The present study was designed to investigate the role of galectin-3 (Gal-3), an important regulator of multiple apoptotic pathways.
The Effects of Monomers Used in Polymeric Biomaterials on Renal Tissue/ Efectos de los Monomeros de los Biomateriales Polimericos Utilizados en Tejido Renal
Background: Galectin-3 (Gal-3) plays a role in the mechanisms underlying ocular venous malformation.
Pingyangmycin Pretreatment Influences the Biological Behavior of Ocular Venous Malformation and Relates with Galectin-3 Expression
Our objective was to investigate the role of Galectin-3 in fine needle aspirates of thyroid nodules as a prospective diagnostic marker and consequently its ability to differentiate benign from malignant neoplasms.
A study of Galactin-3 on fine needle aspiration as a diagnostic marker differentiating benign from malignant thyroid neoplasm
As a potentially novel biomarker, regarding the underlying pathophysiology, galectin-3, a soluble [beta]-galactoside binding lectin, affects the vascular integrity in multiple ways.
Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study
BGM's BGM Galectin-3 is a diagnostic test, which measures galectin-3 levels in blood plasma or serum.
Newly released market study: BG Medicine, Inc. (BGMD) - Product Pipeline Analysis, 2016 Update
Galectin-3 is the only chimera galectin in vertebrates, and it has been widely studied.
LGALS3 and AXIN1 gene variants playing role in the Wnt/[beta]-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer
Galectin-3 is an animal lectin associated with tumor adhesion, angiogenesis, progression, and metastasis and binds to [beta]-galactoside.
The role of parafibromin, galectin-3, HBME-1, and Ki-67 in the differential diagnosis of parathyroid tumors
Galectin-3 plays a major role in diseases that involve scaring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system.
Galectin Therapeutics begins Phase 2 clinical trial of GR-MD-02 in patients with advanced fibrosis NASH (the NASH-FX trial)
Galectin-3 is a member of the lectin family, expressed predominantly by macrophages.
Prognostic values of cardiac biomarkers screening in dialysis patients
Bristol-Myers Squibb and Galecto Biotech AB announced that the firms, along with the Galecto stakeholders, have entered into a deal that provides the former with the exclusive option to buy Galecto Biotech AB and gain global rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in first phase of development to treat idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions.
United States : Bristol-Myers Squibb, Galecto Biotech enter $444M acquisition deal

Medical browser ?
Full browser ?